Puretech Health Share Discussion Threads

[edwardt] 07/10/2022 11:12

any thoughts on this? i guess there is real overlap in their pipeline and expertise in immunology and there probably are synergies.For me, it is not really what we want though as our balance sheet is rock solid and is a comfort. fwiw it is a merger in my head unless they load up on debt to buy us out which i see as very unlikely given the state of the debt markets.

[edwardt] 07/10/2022 09:00

looks to me like we will be bigger partner in merger. they have cut staff etc aggressively. i guess we have to await events but agree large institutions are in no mood to double down and would probably prefer daphne keeps focused internally to find value...

[bad gateway] 07/10/2022 08:43

Was resting lol

[bad gateway] 07/10/2022 08:42

resting on the 200dma. Wonder if they had an early doors trader taking advantage to sell on the news? Rather large one if it was.

[74tom] 07/10/2022 08:38

It's not mad at all, the market is pricing in a likely all-share deal because Nektar don't have the capital to buy PRTC outright...



Cash of ~$630m at 30/06 and they had burned through $160m in the prior 6 month period... PRTC has a market cap of $685m at 218p.. it's not difficult to do the maths and realise the offer will be in Nektar shares. Do big PRTC holders want to own Nektar shares? The answer appears to be no...

[deanmatlazin] 07/10/2022 08:34

it is going down that way

[babbler] 07/10/2022 08:34

where does it say 2 quid a share offer?

[deanmatlazin] 07/10/2022 08:29

i thought the offer should be £5/share at least and NOT £2/share. Are they having a laugh?

[deanmatlazin] 07/10/2022 08:08

first time i see takeover target and the price is going down!

[74tom] 07/10/2022 08:04

Nektar Therapeutics have a market cap of $633m, so any hope of a significant premium looks to be a long shot...

[babbler] 07/10/2022 07:37

RNS out. Rumours true. Discussions ongoing. No price given.

[lendmeafiver] 06/10/2022 19:59

We have had a few of the rumours before that have come to nothing plus it’s back down to 30 on the Nasdaq from 36.

[edwardt] 06/10/2022 19:43

Hmm - let's see. It will have also have to be north of £5 to get me to sit up

[tonysss13] 06/10/2022 18:21

Bid rumours

[edwardt] 28/9/2022 16:21

true i guess only issue is uk fund managers who have outflows own it.

[rambutan2] 28/9/2022 14:37

This is a 100% US$ company - apart from the LSE listing. In £s no rise is a fall.

[edwardt] 14/9/2022 21:05

Yeah - always struck me as nuts giving kids speed - what possibly could go wrong?

[rambutan2] 12/9/2022 11:22

Chamath gives Akili a mention, on this influential pod.

1:03:46 Overprescribing of amphetamines to children

[edwardt] 05/9/2022 13:01

lyt 100 looks like it could be a blockbuster! long way to go though.

[rambutan2] 22/8/2022 14:05

So less cash raised than originally hoped for, as all SPAC cash was redeemed. But on the bright side, does mean that PRTC keeps hold of a bigger slice of what could be a nicely profitable pie:

The transaction implies a post-money equity value of the combined company of up to approximately $1 billion and is expected to deliver up to $412 million in gross cash proceeds to the Company, including the contribution of up to $250 million of cash held in SCS’s trust account and $162 million from PIPE investors at $10 per share. All references to available cash from the trust account and retained transaction proceeds are subject to any redemptions by the public shareholders of SCS and payment of transaction expenses. Akili plans to use the net proceeds to help fund the Company’s go-to-market strategy, to further advance its pipeline of prescription digital therapeutics targeting a range of chronic and acute cognitive disorders, and for other general corporate purposes.

Existing Akili shareholders will roll 100% of their equity into the combined company and will be eligible to receive additional SCS shares pursuant to an earnout based on the combined company’s future stock performance.Chamath Palihapitiya is expected to join Akili’s board of directors as chair, upon the close of the transaction.The proposed business combination, which has been unanimously approved by the boards of directors of both Akili and SCS, is expected to close in mid-2022, subject to approval by SCS’s and Akili’s shareholders, regulatory approvals, and other customary closing conditions.

[74tom] 22/8/2022 09:07

“Following the closing of the business combination, PureTech holds 12,549,207 shares of Akili common stock“

Anyone spot that Akili went crazy after hours Friday hitting $40?! That would value PRTC’s holding at £425m / £1.50 a share… I presume PRTC will reduce their holding if big volume hits Akili today…

[edwardt] 19/8/2022 15:52

will be interesting if the buyback was active today. lots of vol. would obviously be more bullish if it was not them picking them up.

[edwardt] 19/8/2022 10:08

buy back got quite a long way to go. seems given the superb news at karuna and the bolstering of the balance sheet with yet more cash - the market is using this as a place to hide.